Immune checkpoint inhibitors have transformed cancer treatment, producing long-lasting—and sometimes curative—responses in patients with advanced malignancies. Yet only a minority of patients benefit, particularly those whose tumors have spread to the liver, where immunotherapy often proves less effective.
A new preclinical study from researchers at the German Cancer Research Center in Heidelberg suggests the answer may lie not within the cancer cells themselves, but in a specialized population of cells lining the tumor’s blood vessels. The findings, published in Cancer Research, identify lipoprotein lipase (LPL)-expressing tumor endothelial cells as critical regulators of T-cell infiltration into liver metastases and point to a new strategy for enhancing immunotherapy in tumors that are otherwise resistant to treatment.
The discovery builds on growing evidence that remodeling tumor blood vessels can improve immunotherapy. Anti-angiogenic agents such as bevacizumab, which targets the VEGF pathway, have already demonstrated clinical benefit when combined with immune checkpoint blockade. In the landmark IMbrave150 trial, atezolizumab plus bevacizumab significantly improved overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma.
Despite that success, durable responses remain relatively uncommon. Approximately 30% of patients experienced an objective response to the combination therapy, while only about eight percent achieved a complete response. Those results suggest that targeting VEGF alone does not fully overcome the barriers preventing immune cells from reaching and attacking tumors.
To better understand those barriers, the investigators analyzed how blood vessel cells within and surrounding liver metastases responded over time after T-cell therapy. Their analyses uncovered a previously unrecognized subgroup of tumor endothelial cells that express LPL, an enzyme best known for its role in fat metabolism but not previously linked to antitumor immunity.
Rather than serving as passive conduits for blood flow, these endothelial cells actively orchestrated the immune response.
The researchers found that LPL-positive endothelial cells helped activated CD8-positive T cells leave the bloodstream and enter metastatic tumors. Once there, the T cells were able to recognize and destroy cancer cells, leading to regression of liver metastases in mouse models.
The study also revealed why these specialized blood vessel cells appear to be so important. Many cancers evade immune attack by reducing expression of major histocompatibility complex class I (MHC-I), the molecular display system that allows T cells to recognize tumor-derived proteins. Without adequate antigen presentation, even activated T cells struggle to identify malignant cells.
The authors found that LPL-positive endothelial cells compensate for this weakness. Instead of relying solely on tumor cells to present antigens, the endothelial cells themselves captured tumor proteins and displayed them through MHC-I, effectively providing T cells with the information needed to locate nearby cancer cells.
As the authors write, “LPL enhanced MHC-I-dependent cross-presentation of tumor antigens on tumor endothelial cells, thereby promoting T-cell infiltration.”
That interaction created a positive feedback loop. Once activated T cells recognized antigens displayed by the endothelial cells, they also targeted those blood vessel cells, further amplifying immune activity within the tumor microenvironment.
Genetic experiments reinforced the importance of the pathway. Increasing LPL expression specifically in endothelial cells enhanced T-cell infiltration into liver metastases, while eliminating LPL from those cells impaired immune cell recruitment and reduced the effectiveness of T-cell–mediated tumor control.
Importantly, the findings extended beyond animal models.
When the investigators examined human liver metastasis samples, they observed that tumors containing higher numbers of LPL-positive blood vessels also contained significantly more infiltrating T cells, suggesting that the mechanism may operate in patients as well.
The authors conclude that “LPL-positive tumor endothelial cells orchestrate activated CD8-positive T-cell homing into immunologically cold tumors with low baseline MHC-I expression.”
The work also helps explain why vascular-targeted therapies benefit only a subset of patients receiving immunotherapy. Previous research has largely focused on normalizing abnormal tumor blood vessels or increasing expression of molecules that help immune cells adhere to vessel walls. While those approaches improve immune cell access, they do not address another fundamental obstacle: many tumors simply fail to present enough antigens for T cells to recognize.
By acting as surrogate antigen-presenting cells, LPL-positive endothelial cells appear capable of overcoming that limitation, enabling T cells to infiltrate tumors that would otherwise remain immunologically “cold.”
The findings suggest that future combination strategies may need to extend beyond VEGF inhibition and instead directly promote the immune-supporting functions of tumor blood vessels.
Although additional studies will be needed to determine whether therapies can safely increase LPL activity in patients, the work identifies the protein as both a potential biomarker and a therapeutic target. Measuring LPL-positive blood vessels could help identify patients most likely to benefit from immunotherapy combinations, while therapies that enhance this endothelial cell program could potentially expand responses among patients whose tumors currently resist immune attack.
As the authors conclude, enhancing antigen presentation by tumor endothelial cells “presents a promising approach to compensate the intrinsic inability of tumor cells and boost antitumor immunotherapy,” offering a potential new avenue for turning immunologically cold liver metastases into tumors that respond to immune-based treatment.
The post New Target on Tumor Blood Vessels Could Expand Immunotherapy Responses appeared first on Inside Precision Medicine.